Irinotecan and cisplatin versus etoposide and cisplatin in small-cell lung cancer: JCOG 9511

Clinical Lung Cancer

Volumn 2, Issue 1, 2000, Pages 23-24

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; IRINOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; IN VITRO STUDY; JAPAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0034464751     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-7304(11)70610-6     Document Type: Article

References (4)

1. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer
2. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells
3. Irinotecan in cancers of the lung and cervix
4. Randomized phase III study of irinotecan (CPT-11) and cisplatin versus etoposide and cisplatin in extensive disease small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG9511)